- Home
- EVC vs DRUG Comparison
EVC vs DRUG Comparison
Compare EVC & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVC
- DRUG
- Stock Information
- Founded
- EVC 1996
- DRUG 2019
- Country
- EVC United States
- DRUG United States
- Employees
- EVC N/A
- DRUG N/A
- Industry
- EVC Broadcasting
- DRUG Pharmaceuticals and Biotechnology
- Sector
- EVC Industrials
- DRUG Health Care
- Exchange
- EVC Nasdaq
- DRUG Nasdaq
- Market Cap
- EVC 229.5M
- DRUG 260.6M
- IPO Year
- EVC 2000
- DRUG N/A
- Fundamental
- Price
- EVC $2.20
- DRUG $35.99
- Analyst Decision
- EVC Hold
- DRUG Strong Buy
- Analyst Count
- EVC 1
- DRUG 4
- Target Price
- EVC $1.75
- DRUG $84.33
- AVG Volume (30 Days)
- EVC 230.5K
- DRUG 69.2K
- Earning Date
- EVC 03-04-2025
- DRUG 03-04-2025
- Dividend Yield
- EVC 9.09%
- DRUG N/A
- EPS Growth
- EVC N/A
- DRUG N/A
- EPS
- EVC N/A
- DRUG N/A
- Revenue
- EVC $1,146,066,000.00
- DRUG N/A
- Revenue This Year
- EVC N/A
- DRUG N/A
- Revenue Next Year
- EVC N/A
- DRUG N/A
- P/E Ratio
- EVC N/A
- DRUG N/A
- Revenue Growth
- EVC 122.49
- DRUG N/A
- 52 Week Low
- EVC $1.33
- DRUG $0.93
- 52 Week High
- EVC $3.92
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- EVC 46.64
- DRUG 43.58
- Support Level
- EVC $2.14
- DRUG $40.10
- Resistance Level
- EVC $2.30
- DRUG $47.50
- Average True Range (ATR)
- EVC 0.08
- DRUG 3.56
- MACD
- EVC 0.01
- DRUG -0.51
- Stochastic Oscillator
- EVC 50.00
- DRUG 23.22
About EVC Entravision Communications Corporation
Entravision Communications Corp is a global advertising solutions, media, and technology company. Its operations encompass integrated marketing and media solutions, comprised of television, radio, and digital properties and data analytics services. The company operates in television broadcasting, audio broadcasting, and digital media segments. The Company's digital segment, whose operations are located in Europe, Latin America, Asia, the United States, and Africa. The Company's television and audio operations reach and engage U.S. Hispanics in the United States.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.